RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

ReShape Lifesciences ROE 2024

ReShape Lifesciences ROE

-1.71

ReShape Lifesciences Dividend yield

Ticker

RSLS

ISIN

US7611236032

In 2024, ReShape Lifesciences's return on equity (ROE) was -1.71, a -86.46% increase from the -12.63 ROE in the previous year.

ReShape Lifesciences Aktienanalyse

What does ReShape Lifesciences do?

ReShape Lifesciences Inc is a medical company that was founded in 2018 and is headquartered in San Clemente, California. The company is involved in the development and marketing of medical devices for the treatment of obesity and metabolic disorders. The company's business model focuses on innovative medical devices and services for the treatment of obesity and metabolic disorders. The company's main goal is to help patients improve their weight and health in a non-surgical way. The company offers not only medical devices but also services such as physician consulting, training for medical professionals, and patient support. The company's core products include the ReShape Vest, a non-invasive weight loss therapy approach, and the ReShape Duo System, a secondary gastric balloon system used in combination with a dietary program to support weight reduction. The company also offers the ReShape Care Plan, a comprehensive program for patients with obesity that is managed by a multidisciplinary team. The program includes individual sessions with a certified dietitian and a behavioral coach to motivate patients through concrete guidance for weight reduction. ReShape Lifesciences is dedicated to research and development of medical devices and services that help patients in weight reduction and improving their health. The company aims to create an affordable, safe, and effective treatment for obesity patients in an innovative manner that aligns with healthcare reform. ReShape Lifesciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding ReShape Lifesciences's Return on Equity (ROE)

ReShape Lifesciences's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing ReShape Lifesciences's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

ReShape Lifesciences's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in ReShape Lifesciences’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about ReShape Lifesciences Stock

What is the ROE (Return on Equity) of ReShape Lifesciences this year?

The ROE of ReShape Lifesciences this year is -1.71 undefined.

How has the Return on Equity (ROE) of ReShape Lifesciences developed compared to the previous year?

The ROE of ReShape Lifesciences has increased by -86.46% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of ReShape Lifesciences?

A high ROE indicates that ReShape Lifesciences generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of ReShape Lifesciences?

A low ROE can indicate that ReShape Lifesciences is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of ReShape Lifesciences affect the company?

A change in ROE (Return on Equity) of ReShape Lifesciences can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of ReShape Lifesciences?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of ReShape Lifesciences?

Some factors that can influence ReShape Lifesciences's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does ReShape Lifesciences pay?

Over the past 12 months, ReShape Lifesciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ReShape Lifesciences is expected to pay a dividend of 0 USD.

What is the dividend yield of ReShape Lifesciences?

The current dividend yield of ReShape Lifesciences is .

When does ReShape Lifesciences pay dividends?

ReShape Lifesciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ReShape Lifesciences?

ReShape Lifesciences paid dividends every year for the past 0 years.

What is the dividend of ReShape Lifesciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ReShape Lifesciences located?

ReShape Lifesciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von ReShape Lifesciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ReShape Lifesciences from 5/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/28/2024.

When did ReShape Lifesciences pay the last dividend?

The last dividend was paid out on 5/28/2024.

What was the dividend of ReShape Lifesciences in the year 2023?

In the year 2023, ReShape Lifesciences distributed 0 USD as dividends.

In which currency does ReShape Lifesciences pay out the dividend?

The dividends of ReShape Lifesciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ReShape Lifesciences

Our stock analysis for ReShape Lifesciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ReShape Lifesciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.